Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing · New York

ONY Biotech

Amherst, NY · ~40 workers · 9 years of OSHA Injury Tracking Application data.

C
Average Safety Record
2.8
Avg TCR
3.3
Industry avg
0
Fatalities
Subscribe to safety-record updates (RSS)

The verdict

ONY Biotech runs at 85% of its industry's injury rate - about level with the typical Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing workplace, earning a grade C.

ONY Biotech: 2.8 TCR = 85% of Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing BLS 3.3 · 9y Form 300A (see methodology below)

ONY Biotech safety composite

ONY Biotech scores strongest on fatalities (safer than 50% of same-industry peers) and weakest on dart rate (safer than 15%), blended into one 0-100 breakdown against same-industry peers. A missing measure drops out and redistributes its weight rather than deflating the score. This is a per-dimension breakdown, distinct from the single letter grade above it (which weights TCR alone against the BLS industry benchmark).

F

29/100

Percentile-weighted across 3 of 3 measures

Total Case Rate (TCR)
F 2.8 per 100 workers

Safer than 29% of industry peers

DART rate
F 3.09 per 100 workers

Safer than 15% of industry peers

Fatalities
D 0

Safer than 50% of industry peers

Benchmarked live against every credibly-rated employer in the same NAICS industry code in the current OSHA extract (a segment must have at least 8 rated peers to benchmark). Not a legal or compliance determination; PlainSafetyScore's own weighting (TCR 40%, DART 35%, fatalities 25%).

Rising injury rate

ONY Biotech: 2.0 → 3.1 TCR

Peak year 2022 @ 7.7 TCR · DART/TCR 1.1× in 2024

ONY Biotech's TCR rose 1.1 from 2.0 in 2016 to 3.1 in 2024. Peak filing year was 2022 at 7.7 TCR. In 2024, DART was 1.1× this establishment's average TCR (severity share of cases).

OSHA ITA Form 300A scorecard

Establishment book 325412 · Amherst, NY AT/BELOW-IND · SMALL

Grade C · TCR 2.8 · 85% of ind

  • DART 3.1 DART
  • RANK #35/64
  • PHOTO Building 2033
  • BOOK 9y book
  • INJ 10 inj
  • SIZE ~40 FTE

Nearest TCR peer: Building 2033 (0.0 TCR gap)

Read with this employer → · Industry book → · New York employers → · Look up another →

ONY Biotech in the TCR neighbourhood

Average Total Case Rate among this establishment and nearest same-industry peers

TCR

What this shows ONY Biotech averages 2.8 TCR (85% of the Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing BLS benchmark).

Source U.S. Department of Labor, OSHA Injury Tracking Application (Form 300A) As of 2026-08-25

ONY Biotech TCR series: 2016=2 · 2017=7.5 · 2018=0 · 2019=0 · 2020=0 · 2021=0 · 2022=7.7 · 2023=4.8 · 2024=3.1 · BLS 3.3

Where ONY Biotech falls in its industry

855 Pharmaceutical preparations (e establishments

Safer than 29% of graded establishments in this industry, whose median TCR is 1.6.

More dangerous than peersSafer than peers

Narrower to New York alone (the establishments it most directly competes with for workers and contracts): ranked #35 safest of 64 Pharmaceutical preparations (e employers in New York.

ONY Biotech (40 employees, TCR 2.8) among 29 same-industry peers, split at the industry median of 171 employees and a TCR of 1.6 2×2 strategic matrix plotting 30 entities by Average employees (X) and Total Case Rate (Y), with a crosshair dividing the plot into four quadrants. Larger & higher-riskSmaller & higher-riskLarger & saferSmaller & safer than peers 01,0002,0003,0004,000 051015 Average employees Total Case Rate ONY Biotech
ONY Biotech (40 employees, TCR 2.8) among 29 same-industry peers, split at the industry median of 171 employees and a TCR of 1.6

ONY Biotech has fewer employees than the Pharmaceutical preparations (e.g., capsu median and a higher injury rate than the industry's median TCR of 1.6. Workforce size and injury rate do not always move together within the same industry -- some of its smaller peers run higher rates than its larger ones, and vice versa.

Year-by-Year Safety Data

Year TCR DART Injuries Illnesses Fatalities
2024 3.1 3.1 1 0 0
2023 4.8 4.8 2 0 0
2022 7.7 7.7 3 0 0
2021 0.0 0.0 0 0 0
2020 0.0 0.0 0 0 0
2019 0.0 0.0 0 0 0
2018 0.0 0.0 0 0 0
2017 7.5 5.0 3 0 0
2016 2.0 0.0 1 0 0

OSHA ITA peer cross-reference

Establishment peer ledger

325412 · NY · Amherst

855 Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing employers nationwide with a credible TCR · 21,008 rated employers in New York with headcount on file · 112 employers in Amherst, NY · 4 cross-state NAT-TCR peers · 4 cross-state NAT-SIZE peers. Closest matches by relationship code are listed below.

Rel Establishment Metric
NAICS-TCR Building 2033 2.8 TCR
NAICS-TCR Ascent Pharmaceuticals 2.8 TCR
NAICS-TCR Thermo Fisher Scientific 2.8 TCR
NAICS-TCR DDS Caribbean Corp. 2.8 TCR
STATE-SIZE Bilow Farms, LLC 40 FTE
STATE-SIZE Farm 40 FTE
STATE-SIZE Constantine Construction and Farm, Inc. 40 FTE
STATE-SIZE Burrows Bros. Inc. 40 FTE
CITY-NEAR Davis-Ulmer Sprinkler Company Inc 909 FTE
CITY-NEAR Wegmans Alberta Dr 082 570 FTE
CITY-NEAR Alberta Drive 564 FTE
CITY-NEAR Wegmans Niagara Falls 086 452 FTE
NAT-TCR At Home Stores #29 2.8 TCR
NAT-TCR Azalea Hills 2.8 TCR
NAT-TCR Danella Construction Corporation of Pennsylvania 2.8 TCR
NAT-TCR Chesterfield County Schools 2.8 TCR
NAT-SIZE Clemmons Pallet & Skid Works, Inc. 40 FTE
NAT-SIZE Eastern Store 40 FTE
NAT-SIZE Fort Apache Store 40 FTE
NAT-SIZE Quirk Wire Co. Inc. 40 FTE

Rel codes: NAICS-TCR · STATE-SIZE · CITY-NEAR · NAT-TCR/NAT-SIZE cross-state. Read with this employer →

Data Source: OSHA Injury Tracking Application (ITA), mandatory establishment-level injury/illness reports. Grades compare employer Total Case Rate (TCR) to BLS IIF industry benchmarks. Data covers years reported by this establishment: 2024, 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016. This is publicly available government data - not a legal determination of workplace conditions.
Data sourced from official public datasets. See our methodology for details.